MAY 2011

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/307239

Contents of this Issue


Page 1 of 75

©2010 Alcon, Inc. 12/10 DUR11500JAD U.S. Patent No. 6,114,319 Make DUREZOL ® Emulsion your steroid for post-op care. Unique molecular design optimizes potency and penetration 1-4 Covered on more than 82% of national formularies 5 IMPORTANT SAFETY INFORMATION: Indications and Usage: DUREZOL ® Emulsion is a topical corticosteroid that is indicated for the treatment of infl ammation and pain associated with ocular surgery. Dosage and Administration: Instill one drop into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and continuing throughout the fi rst 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response. Contraindications: DUREZOL ® Emulsion, as with other ophthalmic corticosteroids, is contraindicated in most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Warnings and Precautions: • Intraocular pressure (IOP) increase – Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fi elds of vision. If this product is used for 10 days or longer, IOP should be monitored. • Cataracts – Use of corticosteroids may result in posterior subcapsular cataract formation. • Delayed healing – The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order beyond 28 days should be made by a physician only after examination of the patient with the aid of magnifi cation such as slit lamp biomicroscopy and, where appropriate, fl uorescein staining. • Bacterial infections – Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated. • Viral infections – Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). • Fungal infections – Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Adverse Events: Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL ® Emulsion included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacifi cation, anterior chamber cells, anterior chamber fl are, conjunctival edema, and blepharitis. Please see full prescribing information on adjacent page. BECAUSE HAPPENS

Articles in this issue

Archives of this issue

view archives of Eyeworld - MAY 2011